

Total No. of Questions: 3

Total No. of Printed Pages:2

Enrollment No.....



Faculty of Pharmacy
End Sem (Odd) Examination Dec-2022
PY3CO30 Industrial Pharmacy -II

Programme: B. Pharm.

Branch/Specialisation: Pharmacy

Duration: 3 Hrs.

Maximum Marks: 75

Note: All questions are compulsory. Internal choices, if any, are indicated.

- Q.1
- Define pilot plant. What are the space requirements in pilot plant scale up? 2
 - What is the full form of SUPAC? Explain its significance. 2
 - Define technology transfer. What do you understand from CCP? 2
 - Define drug master file. What is its significance? 2
 - Define regulatory affairs. Name different regulatory authorities in world. 2
 - Define acute toxicity and chronic toxicity. 2
 - Define QMS. Give its significance. 2
 - Define quality guideline. ICH Q9 provide the guidance for _____. 2
 - What is the full form of DCGI? Give examples of central drug testing laboratories? 2
 - What are the requirements for import and registration? 2
- Q.2
- Attempt any two:
- Explain the procedure for pilot plant scale up technique for solid dosage form? 10
 - Define quality risk management? Describe the principle & process along with flow diagram? 10
 - Explain SUPAC guidelines? 5
 - Write a note on analytical method transfer? What are the basic responsibilities of sender unit & receiving unit? 5

P.T.O.

[2]

Q.3 Attempt any seven: Two questions from each section is compulsory.

Section - A

- What are the elements of clinical trial? Describe systematically the protocol of a clinical trial. 5
- Write a note on investigator brochure. 5
- Explain the concept of Investigational New Drug Application (INDA). 5

Section - B

- Write a short note on ICH guidelines. 5
- Define OOS? Explain with flow chart and example. 5
- What do you understand with NABL and GLP? Describe in brief. 5

Section - C

- What do you understand from COPP? Explain in brief. 5
- Define CDSCO. Explain in brief the functions, roles and responsibilities of CDSCO. 5
- Write a note on central drug testing laboratories in India. 5

Marking Scheme
PY3CO30 Industrial Pharmacy -II

Q.1	i)	Definition 1 mark. + 1 mark any two space requirement	2
	ii)	1 mark full form+ 1 mark significance	2
	iii)	Definition 1 mark. + 1 mark CCP	2
	iv)	Definition 1 mark. + 1 mark significance	2
	v)	Definition 1 mark. + 1 mark names of any two authorities	2
	vi)	Definition 1 mark. + 1 mark definition	2
	vii)	Definition 1 mark. + 1 mark significance	2
	viii)	Definition 1 mark. + 1 mark fill in the blanks	2
	ix)	Full form 1 mark. + 1 mark any one example	2
	x)	Import requirement 1 mark. + 1 mark registration requirement	2
Q.2			
	i.	2 marks for Definition, 3 marks for general considerations + 2.5 marks for manufacturing procedure for tablet 2.5 mark for manufacturing process of capsules.	10
	ii.	Definition - 1 mark Principle – 2 marks Process – 4 marks Flow diagram - 5 marks	10
	iii.	a) 1.5 marks Definition, components + 3.5 marks levels of changes	5
		b) 2.5 marks note + 2.5 marks 3 responsibilities each of sender unit & receiving unit	5
Q.3		Section - A	
	i.	2.5 marks for definition, phases of clinical trials + 2.5 marks protocol	5
	ii.	1 mark definition + 4 marks note	5
	iii.	1 mark definition + 4 marks complete concept of INDA	5
		Section - B	
	iv.	1 mark definition + 4 marks different types, short note	5
	v.	1 mark definition + 4 marks flow chart, responsibilities, 1 example	5
	vi.	Definition of NABL 1 mark Definition of GLP 1 mark Description of NABL 1.5 marks Description of GLP – 1.5 marks	5

		Section - C	
	vii.	Definition 1 mark + 4 marks short note	5
	viii.	Definition 1 mark + 4 marks function, role, responsibilities	5
	ix.	2 marks for names of central drug testing labs in India + 3 marks for description	5
